---
document_datetime: 2025-12-02 05:03:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-viatris.html
document_name: zonisamide-viatris.html
version: success
processing_time: 0.1140867
conversion_datetime: 2025-12-27 21:46:12.323702
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zonisamide Viatris (previously Zonisamide Mylan)

[RSS](/en/individual-human-medicine.xml/65904)

##### Authorised

This medicine is authorised for use in the European Union

zonisamide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zonisamide Viatris (previously Zonisamide Mylan)](#news-on)
- [Related information](#related-information-561)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Zonisamide Viatris is a medicine used to treat patients with partial seizures (epileptic fits starting in one part of the brain), including those who have secondary generalisation (where the seizure subsequently spreads to the whole brain). It is used on its own in newly diagnosed adults and as an 'add-on' therapy in adults and children aged six years and above already receiving other anti-epilepsy medicines.

Zonisamide Viatris contains the active substance zonisamide and is a 'generic medicine'. This means that Zonisamide Viatris is similar to a 'reference medicine' already authorised in the EU called Zonegran. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Zonisamide Viatris used?

The medicine can only be obtained with a prescription and is available as capsules.

The dose and how often the medicine is taken depends on the condition being treated and whether the patient is an adult or a child.

For further information, see the package leaflet or contact your doctor or pharmacist.

## How does Zonisamide Viatris work?

The active substance in Zonisamide Viatris, zonisamide, is an anti-epileptic. Epileptic fits are caused by abnormal electrical activity in the brain.

Zonisamide is thought to work by blocking specific pores on the surface of nerve cells called sodium channels and calcium channels, through which sodium or calcium normally enter nerve cells. When calcium and sodium enter nerve cells, electrical impulses can be transmitted between the nerve cells. By blocking these channels, zonisamide is expected to prevent abnormal electrical activity spreading through the brain, thereby reducing the chances of an epileptic fit.

Zonisamide Viatris also acts on the neurotransmitter gamma-aminobutyric acid (GABA, a chemical that allows nerve cells to communicate with each other). This may help to stabilise electrical activity in the brain.

## How has Zonisamide Viatris been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Zonegran, and do not need to be repeated for Zonisamide Viatris.

As for every medicine, the company provided studies on the quality of Zonisamide Viatris. The company also carried out studies that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Zonisamide Viatris?

Because Zonisamide Viatris is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Zonisamide Viatris authorised for use in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Zonisamide Viatris has been shown to have comparable quality and to be bioequivalent to Zonegran. Therefore, the Agency's view was that, as for Zonegran, the benefits outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Zonisamide Viatris?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zonisamide Viatris have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Zonegran also apply to Zonisamide Viatris where appropriate.

As for all medicines, data on the use of Zonisamide Viatris are continuously monitored. Suspected side effects reported with Zonisamide Viatris are carefully evaluated and any necessary action taken to protect patients.

## Other information about Zonisamide Viatris

The European Commission granted a marketing authorisation valid throughout the European Union for Zonisamide Viatris on 31 March 2016.

The name of the medicine was changed to Zonisamide Viatris on 15 October 2024.

Zonisamide Viatris : EPAR - Medicine overview

Reference Number: EMA/536337/2024

English (EN) (140.39 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 27/01/2025

[View](/en/documents/overview/zonisamide-viatris-epar-medicine-overview_en.pdf)

[Other languages (23)](#file-language-dropdown-350)

български (BG) (170.16 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/bg/documents/overview/zonisamide-viatris-epar-medicine-overview_bg.pdf)

español (ES) (102.4 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/es/documents/overview/zonisamide-viatris-epar-medicine-overview_es.pdf)

čeština (CS) (132.58 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/cs/documents/overview/zonisamide-viatris-epar-medicine-overview_cs.pdf)

dansk (DA) (106.27 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/da/documents/overview/zonisamide-viatris-epar-medicine-overview_da.pdf)

Deutsch (DE) (111.13 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/de/documents/overview/zonisamide-viatris-epar-medicine-overview_de.pdf)

eesti keel (ET) (103.95 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/et/documents/overview/zonisamide-viatris-epar-medicine-overview_et.pdf)

ελληνικά (EL) (132.11 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/el/documents/overview/zonisamide-viatris-epar-medicine-overview_el.pdf)

français (FR) (109.37 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/fr/documents/overview/zonisamide-viatris-epar-medicine-overview_fr.pdf)

hrvatski (HR) (124.99 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/hr/documents/overview/zonisamide-viatris-epar-medicine-overview_hr.pdf)

íslenska (IS) (140.39 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/is/documents/overview/zonisamide-viatris-epar-medicine-overview_is.pdf)

italiano (IT) (101.08 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/it/documents/overview/zonisamide-viatris-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (136.63 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/lv/documents/overview/zonisamide-viatris-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (156.66 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/lt/documents/overview/zonisamide-viatris-epar-medicine-overview_lt.pdf)

magyar (HU) (128.68 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/hu/documents/overview/zonisamide-viatris-epar-medicine-overview_hu.pdf)

Malti (MT) (126.87 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/mt/documents/overview/zonisamide-viatris-epar-medicine-overview_mt.pdf)

Nederlands (NL) (103.74 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/nl/documents/overview/zonisamide-viatris-epar-medicine-overview_nl.pdf)

polski (PL) (162.58 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/pl/documents/overview/zonisamide-viatris-epar-medicine-overview_pl.pdf)

português (PT) (102.66 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/pt/documents/overview/zonisamide-viatris-epar-medicine-overview_pt.pdf)

română (RO) (120.9 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/ro/documents/overview/zonisamide-viatris-epar-medicine-overview_ro.pdf)

slovenčina (SK) (122.87 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/sk/documents/overview/zonisamide-viatris-epar-medicine-overview_sk.pdf)

slovenščina (SL) (124.55 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/sl/documents/overview/zonisamide-viatris-epar-medicine-overview_sl.pdf)

Suomi (FI) (99.17 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/fi/documents/overview/zonisamide-viatris-epar-medicine-overview_fi.pdf)

svenska (SV) (99.85 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

27/01/2025

[View](/sv/documents/overview/zonisamide-viatris-epar-medicine-overview_sv.pdf)

Zonisamide Mylan : EPAR - Risk-management-plan summary

English (EN) (101.35 KB - PDF)

**First published:** 06/04/2016

[View](/en/documents/rmp-summary/zonisamide-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Zonisamide Viatris : EPAR - Product Information

English (EN) (562.62 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 22/10/2025

[View](/en/documents/product-information/zonisamide-viatris-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-398)

български (BG) (586.26 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/bg/documents/product-information/zonisamide-viatris-epar-product-information_bg.pdf)

español (ES) (295.29 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/es/documents/product-information/zonisamide-viatris-epar-product-information_es.pdf)

čeština (CS) (432.91 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/cs/documents/product-information/zonisamide-viatris-epar-product-information_cs.pdf)

dansk (DA) (274.68 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/da/documents/product-information/zonisamide-viatris-epar-product-information_da.pdf)

Deutsch (DE) (349.79 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/de/documents/product-information/zonisamide-viatris-epar-product-information_de.pdf)

eesti keel (ET) (435.17 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/et/documents/product-information/zonisamide-viatris-epar-product-information_et.pdf)

ελληνικά (EL) (449.19 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/el/documents/product-information/zonisamide-viatris-epar-product-information_el.pdf)

français (FR) (501.57 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/fr/documents/product-information/zonisamide-viatris-epar-product-information_fr.pdf)

hrvatski (HR) (396.38 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/hr/documents/product-information/zonisamide-viatris-epar-product-information_hr.pdf)

íslenska (IS) (276.04 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/is/documents/product-information/zonisamide-viatris-epar-product-information_is.pdf)

italiano (IT) (414.55 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/it/documents/product-information/zonisamide-viatris-epar-product-information_it.pdf)

latviešu valoda (LV) (318.02 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/lv/documents/product-information/zonisamide-viatris-epar-product-information_lv.pdf)

lietuvių kalba (LT) (701.52 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/lt/documents/product-information/zonisamide-viatris-epar-product-information_lt.pdf)

magyar (HU) (557.09 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/hu/documents/product-information/zonisamide-viatris-epar-product-information_hu.pdf)

Malti (MT) (569.68 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/mt/documents/product-information/zonisamide-viatris-epar-product-information_mt.pdf)

Nederlands (NL) (508.16 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/nl/documents/product-information/zonisamide-viatris-epar-product-information_nl.pdf)

norsk (NO) (339.79 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/no/documents/product-information/zonisamide-viatris-epar-product-information_no.pdf)

polski (PL) (403.59 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/pl/documents/product-information/zonisamide-viatris-epar-product-information_pl.pdf)

português (PT) (244.75 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/pt/documents/product-information/zonisamide-viatris-epar-product-information_pt.pdf)

română (RO) (504.63 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/ro/documents/product-information/zonisamide-viatris-epar-product-information_ro.pdf)

slovenčina (SK) (549.35 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/sk/documents/product-information/zonisamide-viatris-epar-product-information_sk.pdf)

slovenščina (SL) (360.66 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/sl/documents/product-information/zonisamide-viatris-epar-product-information_sl.pdf)

Suomi (FI) (435.25 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/fi/documents/product-information/zonisamide-viatris-epar-product-information_fi.pdf)

svenska (SV) (465.3 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

22/10/2025

[View](/sv/documents/product-information/zonisamide-viatris-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000307344 21/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zonisamide Mylan : EPAR - All authorised presentations

English (EN) (50.39 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 17/10/2024

[View](/en/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-592)

български (BG) (85.53 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/bg/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.32 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/es/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (67.64 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/cs/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.15 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/da/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (50.11 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/de/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (12.08 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/et/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.93 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/el/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (69.77 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/fr/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.1 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/hr/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.43 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/is/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (68.04 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/it/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (51.75 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/lv/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.56 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/lt/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (34.87 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/hu/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (58.6 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/mt/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (49.94 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/nl/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.15 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/no/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (38.15 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/pl/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.78 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/pt/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (52.45 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/ro/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (90.41 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/sk/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.42 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/sl/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (67.51 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/fi/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.14 KB - PDF)

**First published:**

06/04/2016

**Last updated:**

17/10/2024

[View](/sv/documents/all-authorised-presentations/zonisamide-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zonisamide Viatris (previously Zonisamide Mylan) Active substance zonisamide International non-proprietary name (INN) or common name zonisamide Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AX15

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

- Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;
- adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above.

## Authorisation details

EMA product number EMEA/H/C/004127

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Viatris Limited

Damastown Industrial Park Mulhuddart Dublin 15 Ireland

Opinion adopted 28/01/2016 Marketing authorisation issued 31/03/2016 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zonisamide Viatris : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (146.7 KB - PDF)

**First published:** 22/10/2025

[View](/en/documents/procedural-steps-after/zonisamide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Zonisamide Viatris : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (160.76 KB - PDF)

**First published:** 03/04/2017

**Last updated:** 22/10/2025

[View](/en/documents/procedural-steps-after/zonisamide-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Zonisamide Mylan : EPAR - Public assessment report

Adopted

Reference Number: EMA/170957/2016

English (EN) (982.63 KB - PDF)

**First published:** 06/04/2016

**Last updated:** 06/04/2016

[View](/en/documents/assessment-report/zonisamide-mylan-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Zonisamide Mylan

Adopted

Reference Number: EMA/CHMP/15884/2016

English (EN) (72.69 KB - PDF)

**First published:** 29/01/2016

**Last updated:** 29/01/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-zonisamide-mylan_en.pdf)

#### News on Zonisamide Viatris (previously Zonisamide Mylan)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 January 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-january-2016) 29/01/2016

#### Related information

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/search?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-1=1=EMEAHC0041270000) (initial marketing authorisation)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/10/2025

## Share this page

[Back to top](#main-content)